--- title: "From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry's Reckoning Is Coming" type: "News" locale: "en" url: "https://longbridge.com/en/news/278153635.md" description: "The cannabis industry faces a reckoning as federal regulations tighten around hemp-derived THC products. Executives who rushed into the market may regret their decisions as the FDA prepares to enforce stricter rules, including cease-and-desist letters. While many companies focused on quick profits from intoxicating cannabinoid products, MMJ International Holdings took a different approach by developing FDA-compliant cannabinoid medicines. This divide could lead to a significant shift in the industry, favoring those who prioritize clinical validation over consumer brands." datetime: "2026-03-06T18:47:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278153635.md) - [en](https://longbridge.com/en/news/278153635.md) - [zh-HK](https://longbridge.com/zh-HK/news/278153635.md) --- # From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry's Reckoning Is Coming "Schedule III doesn't lift all boats; it separates medicine from merchandise," said Duane Boise, President & CEO of MMJ International Holdings. "This realignment is about allowing science to operate within a federally coherent structure. MMJ was built specifically for this architecture. We built real medicine while others built storefronts." **WASHINGTON, DC / ACCESS Newswire / March 6, 2026 /** For the past several years, a growing segment of the cannabis industry has chased what many executives believed was the fastest route to profit: hemp-derived THC beverages, gummies, and intoxicating cannabinoid products sold under the **Agriculture Improvement Act of 2018** loophole. The business model looked irresistible. Companies could manufacture intoxicating cannabinoid products derived from hemp, place them in convenience stores, liquor distributors, and e-commerce channels, and avoid the strict federal approval process required for pharmaceutical drugs. **But that gray zone is closing rapidly.** And when it does, many CEOs who rushed into hemp-THC beverages may find themselves wishing they had chosen a different strategy. **The Illusion of the "Hemp Loophole"** The intoxicating hemp market emerged from a narrow interpretation of the 2018 Farm Bill, which legalized hemp containing less than **0.3% delta-9 THC by dry weight**. Entrepreneurs quickly realized something important: Chemically modified cannabinoids like **delta-8 THC, delta-10 THC, and THC beverages** could be produced from hemp-derived CBD and sold nationwide. For a time, regulators struggled to respond. But from a federal law standpoint, the situation has always been precarious. The **U.S. Food and Drug Administration** has repeatedly stated that: CBD cannot legally be marketed as a dietary supplement Cannabinoids intended for therapeutic effects must go through the FDA drug approval process Products making medical claims require clinical validation Despite this, many companies raced ahead. **Why the FDA Is Likely to Act** Federal agencies are now under increasing pressure to restore order to the cannabinoid market. Concerns include: - Mislabeling and inaccurate potency - Synthetic cannabinoid conversion processes - Youth marketing concerns - Lack of safety testing - Interstate commerce violations Once the federal government begins issuing **warning letters and cease-and-desist actions**, the entire hemp intoxicant category could face rapid contraction. And historically, that is how the FDA regulates new markets: **First warnings.** **Then enforcement.** **The CEOs Who Chased the Quick Buck** Many executives focused on short-term consumer trends. Cannabis beverages appeared attractive because they resemble alcohol distribution models. But there is a fundamental regulatory difference: Alcohol is federally legal. Intoxicating cannabinoids remain regulated under the **Controlled Substances Act**. Companies building billion-dollar beverage brands may soon discover that federal drug law ultimately determines the rules of the game. When enforcement begins, the industry narrative will shift quickly from celebration to regret. **The Pharmaceutical Path Most Companies Ignored** While the hemp beverage boom unfolded, a very small number of companies pursued a far more difficult path. The **FDA drug development pathway.** That path requires: - Pre-clinical toxicology studies - Investigational New Drug (IND) applications - Controlled clinical trials - Standardized dosage forms - Pharmaceutical manufacturing controls Most cannabis companies avoided this route because it takes **years of scientific work and regulatory discipline**. But one company committed to it early. **Why MMJ International Holdings Took the Hard Road** **MMJ International Holdings** focused on building cannabinoid medicines that could meet federal drug standards. Rather than selling unregulated consumer products, the company pursued: - • FDA IND filings - Orphan Drug Designations for Huntington's disease and Multiple Sclerosis - Pharmaceutical-grade manufacturing - Standardized soft-gel dosage forms This strategy aligns with the same regulatory framework that produced the FDA-approved cannabinoid drug **Epidiolex**. The difference is simple. Most companies built **brands.** MMJ built **medicine.** Schedule III Could Accelerate the Divide If cannabis is ultimately reclassified under the Controlled Substances Act, the industry could split into two very different sectors. One side: Retail cannabis products beverages gummies consumer brands The other: Clinical cannabinoid medicines pharmaceutical formulations FDA-approved therapies History suggests that the second category ultimately commands **far greater long-term value**. **The Moment of Realization** When regulators finally draw a clear line between consumer cannabinoids and pharmaceutical cannabinoids, many executives may realize something uncomfortable: They spent years building products that could disappear with a single regulatory action. Meanwhile, companies that invested in clinical research may emerge as the long-term winners. **The Lesson for the Industry** Regulatory shortcuts rarely last forever. Science-based medicine does. And as federal oversight tightens, the companies that invested in clinical validation rather than gray-market loopholes will be the ones defining the next era of cannabinoid therapeutics. **CONTACT:** Madison Hisey MHisey@mmjih.com 203-231-8583 **SOURCE:** MMJ International Holdings View the original press release on ACCESS Newswire ### Related Stocks - [TOKE.US](https://longbridge.com/en/quote/TOKE.US.md) - [MJ.US](https://longbridge.com/en/quote/MJ.US.md) - [CNBS.US](https://longbridge.com/en/quote/CNBS.US.md) - [YOLO.US](https://longbridge.com/en/quote/YOLO.US.md) ## Related News & Research - [EQUATOR Beverage Company Reports First Quarter 2026 Financial Results | MOJO Stock News](https://longbridge.com/en/news/282661330.md) - [America’s highway funding faces a crunch without new federal action](https://longbridge.com/en/news/282415014.md) - [16:20 ETLast Call for Alcohol? How America Is Trading Its Drinks for Cannabis -- Just in Time for 4/20](https://longbridge.com/en/news/282894982.md) - [Pure Oasis closes amid mounting debts, frozen account](https://longbridge.com/en/news/282752325.md) - [Security Federal Corporation Announces Special Dividend | SFDL Stock News](https://longbridge.com/en/news/282885447.md)